.png)
MeMed
FDA-cleared host-immune-response test (bacterial vs viral) at the point of need
Latest event found: 9 Oct 2026 · 11 days ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
MeMed is advancing from an FDA-cleared bacterial-versus-viral diagnostic toward a broader acute-care host-response platform, with recent emphasis on capillary testing, sepsis severity prediction, international adoption, and national AI-enabled biobank infrastructure.
Efficiency Ratio
The company appears to convert a relatively focused team into substantial regulatory, clinical, grant-funded, and commercialization output, although public evidence of revenue scale and sustained customer volume remains limited.
Evidence Signals
MeMed Key received a 2026 Good Design Award Gold recognition in the Engineering Design category through its collaboration with Invetech.
Tampa General Hospital became the first academic health system in the southeastern United States to adopt MeMed host-response technology for sepsis care.
Health Canada approved MeMed BV for use on the MeMed Key platform, expanding the product's regulatory footprint.
The FDA granted Breakthrough Device Designation to MeMed BV Flex, a capillary-blood version of the bacterial-versus-viral infection test.
MeMed was awarded a $2 million competitive national grant through the Israel Innovation Authority to establish an acute-care diagnostics and proteomics biobank supporting nationwide AI research infrastructure.
MeMed BV was trialed in a United Kingdom NHS-funded study involving children with suspected infection, including evaluation relevant to sepsis and meningitis diagnosis.
- About
- Israeli med-tech / bio-convergence company (HQ Haifa, Israel; US operations in Andover/Boston, MA), founded around 2009 by Eran Eden (CEO) and Dr. Kfir Oved (both Technion). MeMed decodes the body's host immune response into rapid diagnostic scores. Its MeMed BV® is the first FDA-cleared host-response test to distinguish bacterial from viral infection in ~15 minutes (measuring TRAIL, IP-10, CRP) on the point-of-need MeMed Key® analyzer; the pipeline adds MeMed Severity™ (FDA Breakthrough Device Designation for predicting deterioration/sepsis) and the fingerstick MeMed BV Flex™ (Breakthrough Device Designation, 2026). Raised >$200M (incl. a $93M round) with direct support from the US Department of Defense and the EU Commission. Point-of-need infection/sepsis triage and antimicrobial stewardship make it a strong dual-use combat-casualty-care fit.
- Tags
- #hostresponse #diagnostics #sepsis #bacterialviral #pointofcare #ivd #ml #fda #dod #amr #dualuse